SHATTUCK LABS INC (STTK)
Health Care · Clinical-stage monoclonal antibody therapeutics · NASDAQ
Shattuck Labs is a clinical-stage biotech developing novel protein therapeutics to treat inflammatory and immune-mediated diseases by targeting the DR3/TL1A pathway.
What SHATTUCK LABS INC does
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases. The company's lead program, SL-325, is a high-affinity DR3 blocking monoclonal antibody designed to achieve more complete blockade of the DR3/TL1A pathway compared to TL1A blocking antibodies currently in development. The company believes its DR3-targeting approach offers potential advantages in clinical remission rates, durability of effect, and a superior immunogenicity profile versus competing TL1A blockers.
Themes: Inflammatory bowel disease (IBD) / Crohn's disease, Immune-mediated diseases, DR3 receptor antagonism, Monoclonal antibodies, TNF receptor pathway
Fundamentals
- Price$7.53 as of 2026-08-21 close
- Market cap$756M as of 2026-08-21
- 1-year return+741.3% 2025-08-21 close $0.895 → 2026-08-21 close $7.53
- P/En/a negative earnings
- Net margin-1005.6% as of 2026-08-24
- ROE-60.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-78.3% as of 2026-08-24
- Revenue CAGR (3y)+15.3% SEC XBRL
- Beta0.99 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How STTK compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SHATTUCK LABS INC looks technically
SHATTUCK LABS INC (STTK) is trading 46.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 227 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 14 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 42% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 46.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +46.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.69 | $6.69 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.13 | $5.13 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 6.93. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 227 trading days ago — a "golden cross", a bullish long-term signal | 227 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control | 25.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($6.93 to $7.94) — its "stochastic" reading is 59 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 59.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.33 | $8.33 |
|---|---|---|
| From the 52-week high | it is 9.6% below its 52-week high (its highest price of the past year) | -9.6% |
| Above the 52-week low | it is 853.2% above its 52-week low (its lowest price of the past year) | +853.2% |
| Below the 52-week high | it is 9.6% below its highest point of the past year | 9.6% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $46.76 (set on 2021-02-22) | $46.76 |
| Given back of the 52-week move | over the past year its closes ranged ($0.8604 to $7.92), and it has given back only a small part of its rise from last year’s low — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.33 to $3.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.5% |
| From the all-time high | it is 83.9% below its all-time high | -83.9% |
| Nearest price level | it is trading 1.5% below a resistance level at $7.64 — a price it turned at twice since 2026-04-09, most recently on 2026-07-06. Since 2024-08-21 it has 11 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.5% |
| All-time low | its lowest closing price on record is $0.692 (set on 2025-04-07) | $0.692 |
| Above the all-time low | it is 988.2% above its all-time low | +988.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4996 between its high and its low — about 6.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4996 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.76 and $7.81 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.76 – $7.29 – $7.81 |
| Typical daily range (% of price) | its price moves about 6.6% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.6% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges above its 200-day average price (46.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 42% of its 30-day average | 0.42× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.9% since the prior reading | -0.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Open gap | it gapped 6.9% above the previous close 48 sessions ago and has not traded back through the level it left behind at 4.18 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.9% |
| Gap filled | a 3.2% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.1 percentage points (the stock gained 4.4% while the market gained 2.3%) | +2.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.5 percentage points (the stock gained 23.6% while the market gained 3.1%) | +20.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 76.7 percentage points (the stock gained 87.8% while the market gained 11.1%) | +76.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 720.9 percentage points (the stock gained 741.3% while the market gained 20.5%) | +720.9% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.4% of the share price. | +22.5% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 26% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $6.00 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +25.5% |
|---|
Price levels it has turned at before
STTK last closed at $7.53 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.64 | Resistance | 1.5% above the last close | turned there twice · 2026-04-09 to 2026-07-06 |
| $5.74 | Support | 23.8% below the last close | turned there twice · 2026-03-23 to 2026-05-19 |
| $3.94 | Support | 47.6% below the last close | turned there twice · 2024-09-10 to 2024-09-30 |
| $3.36 | Support | 55.4% below the last close | turned there three times · 2024-09-03 to 2026-06-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $6.93.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $8.31 and $9.16 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $6.93.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$14.25 range $10.00 – $18.00; median $14.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for STTK
- Consensus EPS estimate-$0.1235 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial execution risk: ability to enroll patients and successfully complete Phase 2 trial in Crohn's disease initiating Q3 2026; timing and likelihood of regulatory approvals remain uncertain","Manufacturing and supply risk: ability to manufacture and supply SL-325 for clinical trials and commercial use if approved, including impact of inflationary pressures on R&D and manufacturing costs","Competitive and market risk: competing TL1A blocking antibodies (afimkibart, tulisokibart, duvakitug) are already in clinical development; company must establish superiority of DR3 blocking approach; pricing, coverage, and reimbursement uncertainties for approved products"]
What changed in the latest 10-Q
AI-assisted comparison of STTK's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) shows table of contents page numbers: Item 2 MD&A at page 20, Item 3 at page 28, Item 4 at page 28, PART II starting at page 29, Item 1A Risk Factors at page 29, Item 2 at page 29, Item 3 at page 29, Item 4 at page 29, Item 5 at page 29, Item 6 at page 30, Signatures at page 31
- Newer filing (2026-05-07) balance sheet shows 'Investment in related party' of $1,000 thousand as of March 31, 2026
- Removed:
- Older filing (2025-11-06) had table of contents showing Item 2 MD&A at page 23, Item 3 at page 33, Item 4 at page 33, Item 1A at page 34, Item 2 at page 36, Item 3 at page 36, Item 4 at page 36, Item 5 at page 36, Item 6 at page 37, Signatures at page 38
- Older filing (2025-11-06) balance sheet included 'Investments' of $43,584 thousand as of September 30, 2025 and $15,600 thousand as of December 31, 2024
- Older filing (2025-11-06) balance sheet did not separately list 'Investment in related party' line item
- Reworded:
- Newer filing (2026-05-07) forward-looking statements section: 'and reflect our current views' changed to match older version phrasing more closely; both now include similar language but newer uses 'outcomes or results' vs older 'outcomes, or results'
- Older filing (2025-11-06) lists 'Risk Factors' in forward-looking statements section without quotation marks; newer filing (2026-05-07) uses quotation marks: '"Risk Factors"'
- Newer filing (2026-05-07) states 'changes in trade policies, including tariffs or other trade restrictions or the threat of such actions' vs older filing (2025-11-06) states 'changes in trade policies including tariffs or other trade restrictions, or the threat of such actions' (comma placement differs)
- Newer filing (2026-05-07) balance sheet shows March 31, 2026 and December 31, 2025 comparison dates; older filing (2025-11-06) shows September 30, 2025 and December 31, 2024 comparison dates
- Newer filing (2026-05-07) shows different share counts: 75,581,787 shares at March 31, 2026 and 63,279,843 at December 31, 2025; older filing (2025-11-06) shows 63,151,789 shares at September 30, 2025
- Notes:
- Newer filing (2026-05-07) condensed statements of operations appear truncated in provided text; older filing (2025-11-06) statements of operations also appear truncated, limiting full comparison
- Balance sheet comparison spans different time periods (Q1 2026 vs Q3 2025/Q4 2024) making period-over-period analysis inherently different
- Older filing shows revenue of $1,000 thousand in three-month period and collaboration revenue line item; newer filing shows $0 revenue with incomplete statement data provided
Risk Factors
- Added:
- New Item 5 (Other Information) section disclosing Rule 10b5-1 trading plans adopted by Chief Medical Officer Arunthathy Nirmalini Pandite on February 2, 2026 for up to 83,514 shares, expiring June 30, 2027 or earlier
- New Item 5 disclosing Rule 10b5-1 trading plan adopted by Chief Technical Officer Abhinav Shukla on February 2, 2026 for stock options to purchase up to 168,659 shares, expiring January 29, 2027 or earlier
- New Item 5 statement confirming no other directors or Section 16 officers adopted or terminated trading arrangements during the three months ended March 31, 2026
- New Item 6 Exhibits section listing exhibits including First Amendment to Texas Lease Agreement (10.1) and Second Amendment to Texas Lease Agreement (10.2)
- New signature section dated May 07, 2026 with signatures from Dr. Taylor Schreiber (CEO) and Andrew R. Neill (CFO)
- Removed:
- Risk factor text regarding capital requirements and funding for SL-325 development
- Risk factor text regarding common stock warrants and their exercise implications
- Risk factor text regarding additional capital and management diversion
- Risk factor text regarding FDA disruptions from government shutdowns and leadership changes
- Risk factor text regarding federal government shutdown since October 1, 2025
- Risk factor text regarding laws and regulations affecting drug pricing and commercialization (text appears truncated at 'Und')
- Reworded:
- Changed from 'Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. Other than the risk factors below, there have been no material changes' to 'Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes' - updated fiscal year reference from 2024 to 2025 and removed 'Other than the risk factors below' qualifier
- Notes:
- Older filing text appears truncated or incomplete at the end (cuts off mid-word at 'Und'), limiting ability to assess all changes in risk factors section
- The newer filing contains significantly more content (Items 2-6 and signatures) while the older filing excerpt provided focuses primarily on Item 1A risk factors
- The filing structure and content differ substantially between the two documents, suggesting these may be different sections or complete portions of different 10-Q filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 4 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($250000) · 4 sells ($379305) — 1 buying, 2 selling insiders
- Last 180 days1 buy ($250000) · 6 sells ($591850) — 1 buying, 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-02. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about STTK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding STTK as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,919,595
- Reported value $12,342,996
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
STTK had 6,394,445 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
STTK had 6.37% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.3 days to cover at the same settlement.
- Reported short interest (shares) 6,394,445
- Short interest (% of shares outstanding) 6.37%
- Prior settlement (shares) 7,802,903
- Reported change -18.05%
- Days to cover (reported) 5.3
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Genentech (Roche) - TL1A blocking antibodies in clinical development
- Ionis Pharmaceuticals - TNF pathway targeting
- AbbVie (ABBV) - inflammatory bowel disease therapeutics
- Janssen Biotech - IBD and immune-mediated disease treatments
- Pfizer (PFE) - TNF and immune pathway inhibitors
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare STTK vs…
SHATTUCK LABS INC is found in…
STTK ranks in…
Frequently asked questions
What does SHATTUCK LABS INC (STTK) do?
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific Death Receptor 3 (DR3) blocking antibodies for inflammatory and immune-mediated diseases. The company's lead program, SL-325, is a high-affinity DR3 blocking monoclonal antibody designed to achieve more complete blockade of the DR3/TL1A pathway compared to TL1A blocking antibodies currently in development.
What sector is SHATTUCK LABS INC (STTK) in?
SHATTUCK LABS INC (STTK) is classified in the Health Care sector. Its industry is Clinical-stage monoclonal antibody therapeutics. It trades on NASDAQ.
Who are SHATTUCK LABS INC's (STTK) competitors?
Notable peers of SHATTUCK LABS INC (STTK) include Genentech (Roche) - TL1A blocking antibodies in clinical development, Ionis Pharmaceuticals - TNF pathway targeting, AbbVie (ABBV) - inflammatory bowel disease therapeutics, Janssen Biotech - IBD and immune-mediated disease treatments and Pfizer (PFE) - TNF and immune pathway inhibitors. This peer set is informational only — not financial advice.
Is SHATTUCK LABS INC (STTK) overbought or oversold right now?
SHATTUCK LABS INC (STTK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on STTK come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.